BH15 Efficacy and safety of baricitinib in the management of severe alopecia areata over a 6-month period: a real-world experience

Abstract Alopecia areata (AA) is an autoimmune condition that targets the hair follicles, causing nonscarring loss. It can manifest with different patterns, ranging from discrete bald patches on scalp to complete loss of body hairs. Despite being considered a disease purely aesthetic concern, recent data support its systemic nature. In June 2022, baricitinib, oral selective inhibitor Janus kinases 1 and 2, was first US Food Drug Administration-approved treatment for adult patients severe AA. Our objective present efficacy safety baricitinib in management AA real practice at 24 weeks. All consecutive diagnosed AA, who were started our specialist clinic, completed weeks eligible. Access granted after approval by national organization provision health services case-by-case basis. Demographic data, history, previous treatments comorbidities documented. Severity Tool (SALT) score, eyebrows/eyelashes, other parts nail involvement also assessed. Patients Dermatology Life Quality Index (DLQI), Patient Health Questionnaire (PHQ)-9 Generalised Anxiety Disorder Assessment (GAD-7) each visit. Safety profile Visits performed T1 (4 weeks), T2 (8 T3 (12 weeks) T4 (24 weeks). Ten included analysis. The male-to-female ratio 3 : 2. Mean patient age 34.8 years. White. Sixty per cent had alopecia universalis/totalis, 30% ophiasis 10% patchy alopecia. duration 6.1 most common depression anxiety. Baseline mean SALT score 82, which decreased significantly 8, 12 24. Ninety eyebrow/eyelash regrowth. more onset responded quicker than those chronic course. Nail noted patients, improved all them week There significant decrease PHQ-9, GAD-7 DLQI scores Forty developed acneiform rash, upper respiratory infection, vaginal 40% transient raised creatine kinase, 20% dyslipidaemia neutropenia anaemia. real-world showed quick action encouraging results terms acceptable, many adverse events not requiring treatment. No noted. Studies larger number longer are needed assess long-term everyday clinical practice. Finally, registries could play crucial role.